Evolus Initiates Phase II Program with “Extra Strength” Dose for Extended Duration

NEXT STORY
Akoya Biosciences Announces Founding Members of First-of-its-Kind Imaging Innovators (I²) Network
PREV STORY
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018

FREMONT, Calif., March 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:ST), a ...

author_avatar
NASDAQ Market News

Inovalon Announces Charitable Giving for 2016

BOWIE, Md., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq:INOV), a leading technology company ...

author_avatar
NASDAQ Market News

Following Azedra’s Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update

AZEDRA® (iobenguane I 131) Approved by U.S. Food and Drug Administration (FDA); U.S. Promotion ...

author_avatar
NASDAQ Market News